This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
by Zacks Equity Research
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
Q1 Earnings Drag Pharma ETFs Down
by Sweta Killa
Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.
Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings
by Swarup Gupta
The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).
Company News for May 2, 2018
by Zacks Equity Research
Companies In The News are: PFE,MRK,THC,BP
ADP Job Data, Q1 Earnings In Focus
by Zacks Equity Research
ADP Job Data, Q1 Earnings In Focus
Jobs Week Shows New Wage Growth (and Lack Thereof)
by Mark Vickery
Paychex reported small-business jobs and wage growth for last month, and the results are definitely interesting.
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.
Pfizer (PFE) Q1 Earnings Beat, Sales Miss, 2018 View Intact
by Kinjel Shah
Pfizer (PFE) beat expectations for earnings but missed the same for revenues in Q1. It retained its previously issued guidance for 2018.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
by Zacks Equity Research
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
Amazon (AMZN) Q1 Earnings Crush Estimates, Sales Surge Y/Y
by Zacks Equity Research
Amazon's (AMZN) first-quarter results benefit from robust revenue growth in the AWS segment.
Why Pfizer (PFE) Might Surprise This Earnings Season
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
by Zacks Equity Research
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .
What's in the Offing for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.
Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
by Zacks Equity Research
With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.
Is FlexShares Quality Dividend Defensive Index Fund (QDEF) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for QDEF
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
What's in the Cards for Merck (MRK) This Earnings Season?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer